Invention Grant
- Patent Title: Tetrazolone-substituted dihydropyridinone MGAT2 inhibitors
-
Application No.: US15866871Application Date: 2018-01-10
-
Publication No.: US10093650B2Publication Date: 2018-10-09
- Inventor: Saleem Ahmad
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Jing G. Sun
- Main IPC: C07D401/04
- IPC: C07D401/04 ; A61K45/06 ; A61K31/4439 ; C07D417/14 ; C07D409/14 ; C07D401/14
Abstract:
The present invention provides compounds of Formula (I): a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
Public/Granted literature
- US20180127394A1 TETRAZOLONE-SUBSTITUTED DIHYDROPYRIDINONE MGAT2 INHIBITORS Public/Granted day:2018-05-10
Information query
